By contrast, in vivo modulation of tumor cell morphology, E-cadherin and vimentin levels, and the lack of in vitro inhibition of tumor cell proliferation by the LOXL2 inhibitor, point to a possible EMT function rather than proliferative stimulation of tumor cell growth. Here, CDH1 is linked to neoplasm.